Detail akcie Staar Surgical online

Business Summary: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Financial Summary: BRIEF: For the fiscal year ended 29 December 2023, STAAR Surgical Co revenues increased 13% to $322.4M. Net income decreased 46% to $21.3M. Revenues reflect ICLs segment increase of 18% to $319.4M, China segment increase of 25% to $185.6M, Others segment increase of 3% to $81.2M. Net income was offset by General and administrative - Balancing increase of 33% to $60.2M (expense), Marketing and selling - Balancing value increase of 24% to $57.1M (expense).